Superior mesenteric arterial embolism: local fibrinolytic treatment with urokinase.
OBJECTIVE
To evaluate the efficacy of intraarterial urokinase in the treatment of superior mesenteric arterial (SMA) embolism.


METHODS
Within 3 years, 10 patients (six men, four women; aged 62-82 years) with angiographically proved SMA emboli were selected on the basis of absence of peritoneal signs of intestinal necrosis at physical examination and normal abdominal plain radiographs to undergo local lysis with urokinase.


RESULTS
The procedure was performed without complications in all 10 patients. The embolus was successfully lysed in nine patients (90%). Clinical success was achieved in seven patients (70%); however, in one patient laparotomy was required to confirm the clinical finding. None of these patients had recurrent embolism or postischemic intestinal stenosis during follow-up (mean, 11.2 months). The three remaining patients (30%) underwent laparotomy subsequent to failure of intraarterial treatment with urokinase.


CONCLUSIONS
Fibrinolytic treatment with urokinase may be an effective alternative to surgical embolectomy in patients with SMA embolism without clinical or radiologic signs of intestinal infarction. In this small series, abatement of abdominal pain in the 1st hour of fibrinolytic treatment was the best indicator of clinical success. Pain persisted in patients with intestinal infarction.
Simó
G
G
Department of Radiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Echenagusia
A J
AJ
Camúñez
F
F
Turégano
F
F
Cabrera
A
A
Urbano
J
J
D000368:Aged; D000369:Aged, 80 and over; D004617:Embolism / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D017538:Mesenteric Artery, Superior / Q000000981:diagnostic imaging; D008641:Mesenteric Vascular Occlusion / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008875:Middle Aged; D010960:Plasminogen Activators / Q000627:therapeutic use*; D011859:Radiography; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator